

1614

RECEIVED

JAN 25 2002

TECH CENTER 1600/2900

COPY OF PAPERS  
ORIGINALLY FILED



Pocket No.: ENP-031  
Serial No.: 09/975,923

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Yat Sun Or *et al.*  
U.S. Appl. Serial No.: 09/975,923  
Filing date: October 12, 2001  
Group Art Unit: 1614  
Examiner: TBD  
Title: Cyclosporin Analogs for the Treatment of Lung Diseases

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited today with the United States Postal Service as First Class Mail in an envelope addressed to: Box DD, Commissioner for Patents, Washington, D.C. 20231.

Stacie Capotosto  
Date: 12/18/01

INFORMATION DISCLOSURE STATEMENT

Box DD  
Commissioner for Patents  
Washington, D.C. 20231

Dear Sir/ Madam:

In accordance with the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98 in the aforementioned matter, Applicants wish to bring to the Examiner's attention the following references, references AA, BA and BB, cited on the attached Form PTO-1449 (Rev. 2-32):

- 1) U.S. Patent No. 5,525,590 (ref. AA);
- 2) European Patent Application No. 0296122 A2 (ref. BA); and
- 3) European Patent Specification No. 0296122 B1 (ref. BB).

Doc. No. ENP-031  
Serial No. 09/975,923


In accordance with the provisions of 37 C.F.R. § 1.97, this statement is being filed:

- X   (1) **within three (3) months of the Filing Date** or before the mailing date of the First Office Action on the merits; or
- (2) within three months of the mailing date of the PCT International Search Report; or
- (3) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and the requisite Certification or fee under Rule 1.17(p), namely \$ 180.00, is included herein; or
- (4) after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached Form PTO-1449 (Rev. 2-32) be made of record in this application. Copies of these documents (CHECK ONE):

- X   are enclosed herewith; or
- have been cited in an earlier related application, and need not be submitted herein (courtesy copy enclosed).

Respectfully Submitted by,

  
Sandhya Kalkunte  
Registration No. 46,466

*Enanta Pharmaceuticals, Inc.*  
Tel: (617) 607-0747  
Fax: (617) 607-0535  
Date: December 18, 2001

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-32) PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

ENP-031

SERIAL NO.

09/975,923

APPLICANT

Yat Sun Or *et al.*

FILING DATE

10/12/2001

GROUP

1614

## U.S. PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	U.S. Patent 5,525,590	6/11/96	Bollinger <i>et al.</i>	514	11	11/10/1994

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BA	EP Appln. No. 0296122 A2	12/21/88	Europe				
	BB	EP Spec. No. 0296122 B1	9/29/93	Europe				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

EXAMINER			DATE CONSIDERED



RECEIVED  
JAN 25 2002  
TECH CENTER 1600 2000